Real-world characteristics of patients with sickle cell disease who initiated crizanlizumab therapy.
Payal C DesaiChi-Chang ChenCatherine B McGuinessMarie YasudaSoyon LeeJincy PauloseJing HeGlorian YenPublished in: Current medical research and opinion (2023)
66% of patients who receive crizanlizumab receive at least 4 doses within 6-months. The low median number of gap days suggests high adherence.